Previous close | 0.9171 |
Open | 0.9600 |
Bid | 0.8799 x 100 |
Ask | 0.9258 x 200 |
Day's range | 0.8708 - 0.9600 |
52-week range | 0.6500 - 1.4900 |
Volume | |
Avg. volume | 1,746,788 |
Market cap | 349.901M |
Beta (5Y monthly) | 2.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.08 |
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours. To enhance
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA), including the potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a). ”The data presented at ACC.24 provide new evidence surrounding
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular E